💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Omnipod insulin management system now available for use in Europe with Fiasp

Published 10/02/2018, 06:39 AM
© Reuters.  Omnipod insulin management system now available for use in Europe with Fiasp
NOVOb
-
PODD
-
  • Insulet Corporation (NASDAQ:PODD) announces that Novo Nordisk’s Fiasp (Fast-Acting Insulin Aspart) has been tested and found safe for use in Insulet’s Omnipod System in Europe.
  • Fiasp is a new-generation, ultra fast-acting insulin developed by Novo Nordisk (CO:NOVOb) that enters the bloodstream two times faster, compared to NovoRapid, so it more closely matches a healthy body’s insulin response to a meal, thereby improving glycemic control. Insulet will showcase its Omnipod System during the European Association for the Study of Diabetes (EASD) annual meeting at the Messe Berlin Exhibition Halls in Berlin, Germany taking place 1st October to 5th October 2018.
  • Now read: Dr. Reddy's Lab announces the sale of Cloderm Cream, 0.1% to EPI Health


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.